![]()
- US Markets Bracing for Selloff on Dubai Debt Worries
- US Dollar Falls to 14-Year Low Against the Yen
- No Thanksgiving Rest for Retailers in Sales Race
- UK's Darling to Downgrade 2009 Growth Forecast
- US Companies Already Moving on Curbing Emissions
- Fannie Mae to Tighten Lending Standards: Report
- Investing in Good Karma – and Making a Profit
- Retailers Should Believe in Christmas Miracles
- Bankruptcies Jump, Hitting Highest Level in Four Years
- 4 Thanksgiving Week Buys For Your Portfolio: Market Pros
- There's a 'Great Chance' For a Double-Dip Recession: Strategist
- Revenge of the Gangsta Nerds
- Will TCU See The "Flutie Effect?"
- Retail Earnings and Sales to Improve in Q4: Analyst
- Consumers Catching the Holiday Spirit
- It's Beginning To Look A Lot More Riskless
- Crescenzi: Claims Level Suggests End to Job Losses
- Hedge Funds Take Early Lead in Warren Buffett's 'Big Bet'
MOST SHARED
- Kuoni CEO Sees Recovery in Travel Sector
- Dubai Struggles to Ease Debt Fears; Investors Rattled
- Gold Retreats from Record High as Dollar Rebounds
- China Unveils Carbon Target Ahead of Copenhagen
- US Markets Bracing for Selloff On Worries About Dubai's Debt
- Hyundai-Kia Targets Rapid China Growth in 2010
- No Thanksgiving Rest for Retailers in Sales Race
- Attraction of Switzerland to Businesses
- Great Britain, No Longer That Great: Investor
A cancer vaccine more than doubled the survival time of people with the most common and deadly type of brain tumor, U.S. researchers said.
The vaccine, made by Avant Immunotherapeutics [AVAN
Loading...
()
] and licensed by drug giant Pfizer [PFE
Loading...
()
], enlists the help of the immune system to attack the tumor.
![]() |
AP |
Researchers treated 23 patients with a type of brain tumor called glioblastoma multiforme. They have lived, on average, 33 months, said Dr. John Sampson of Duke University, who presented the study at a meeting of the American Society of Clinical Oncology in Chicago.
"That is almost unheard of," Sampson said in an interview. "We have one woman who has gone on to have two babies now," Sampson said.
Patients given standard therapy alone lived on average 14 months. It also took far longer for tumors to grow back after surgery.
In people treated with the vaccine, this so-called time to progression was 16.6 months, more than double the usual six months.
Glioblastoma multiforme, a serious form of brain tumor of a type known as a glioma, kills half its victims within a year and patients rarely survive more than three years.
Massachusetts Democratic Sen. Edward Kennedy was diagnosed with a malignant glioma last month and the vaccine could be one among several options he might try, Sampson said.
"Kennedy may well be a candidate. We don't know if he is interested at this point," Sampson said in an interview.
Kennedy's office said the senator would be undergoing surgery on Monday at Duke in Durham, North Carolina.
Former Yankees baseball star Bobby Murcer is already being treated with the vaccine.
The vaccine targets a mutation of a very common structure known as a receptor on the tumor cells, the epidermal growth factor receptor. This mutation is only found in cancer, not in normal tissues.
"It is completely tumor-specific," Sampson said in a telephone interview.
The vaccine is coupled with a chemotherapy drug called temozolomide, sold by Schering-Plough [SGP
Loading...
()
] under the brand name Temodar, which is thought to boost the immune response.
"The immune responses these patients are getting are phenomenal," Sampson said.
One of the worries about immune therapies is that the immune system may start attacking itself. So far, that has not happened, Sampson said.
A second study of the vaccine that followed a slightly different design and dosing schedule in 21 patients resulted in a median survival time of 26 months, compared to the typical 15-month survival for similar patients who just got standard therapy.
A larger randomized study is currently enrolling patients at 24 sites across the United States.
The results have been enough to attract the interest of Pfizer Inc, which in April agreed to pay a total of more than $400 million for rights to market the vaccine.
Pfizer, whose stock is at a 10-year-low, is in need of a big win.
"This is probably one of the biggest if not the biggest immunotherapy deals that has been made," Sampson said. "If this works, I think there will be more investment in vaccines," he said.
About 22,000 malignant tumors of the brain or spinal cord will be diagnosed this year in the United States, and about 13,000 people will die from them, according to the American Cancer Society.
- What you need to know.
- Ever wished your cab driver would stop nattering and just get to where you're going? Well that moment is near(er).
- Eric Schmidt pledges to create a virtual copy of the Iraq National Museum at Google’s expense.
- Bill Griffeth is taking a leave of absence from CNBC and Power Lunch for a year. Here's a message from Bill.
- More shoppers than ever plan to comparison-shop this season. Who will benefit?
- It may be the most unusual guide to business you'll read.













